On “Grindeks” financial results in the first half year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
On “Grindeks” financial results in the first half year of 2016

Today, on 26 August, the JSC “Grindeks” submitted the non-audited consolidated financial statements for the first half year of 2016 to “Nasdaq Riga”. Non-audited financial results indicate that the Group’s turnover in the first six months of 2016 was 46.4 million euro and has increased by 2.6 million euro or 5.9% in comparison to the first six months of 2015. In the first six months of 2016, the Group’s net profit, attributable to shareholders of the parent company, was 4.2 million euro and has increased by 1 million euro or 32.4 % compared to the first six months of 2015. Gross profit margin in the first half year of 2016 was 51.1%, while net profit margin was 9.2%. In the first six months of 2016, the Group’s production was exported to 64 countries worldwide, a total of 41.5 million euro which is by 1.7 million euro or 4.2% more than in the first half year of 2015.

Sales volume of the final dosage forms of “Grindeks” in the first half year of 2016 was 42.5 million euro and has increased by 3.4 million euro or 8.7% in comparison to the first half year of 2015. In the first half year of 2016, the sales amount in Russia, other CIS countries and Georgia reached 23.8 million euro, which is by 0.3 million euro or 1.2% more than in the first half year of 2015. After assessment of potential currency risks, “Grindeks” limited its operations in Central Asia countries in the first half year of 2016, thus, the export to these countries was reduced. In comparison to the first six months of 2015, the biggest increase in sales volume has been reached in Russia (25%), Uzbekistan (18%), Moldova (17%) and Turkmenistan (15%).

Due to the business diversification strategy and the development of company’s activities in the new markets, in the first half year of 2016 the sales volume in the Baltic States and other countries reached 18.6 million euro which is by 3.1 million euro or 20.1% more than in the first half year of 2015. The sales volume in Croatia compared with the first six months of 2015 has increased by 7.6 times, in Spain – 4 times, in Canada – 1.8 times, while in Hungary and Finland it has increased by 36%. In the first half year of 2016, the sales volume in Latvia reached 3.8 million euro and has increased by 0.9 million euro or 32.5% in comparison with the first six months of 2015. In the first half year of 2016, compared with the first half year of 2015, remarkable increase in sales have been reached also in the other Baltic States – in Lithuania by 17% and Estonia by 16%.

In the first half year of 2016, in several Eastern European countries, including the Baltic States, the Group of “Grindeks” has registered injectable preparations – Diazepeks®, Neostigmine-Kalceks, Piracetam-Kalceks, Magnesium sulfate-Kalceks and Tramadol-Kalceks. In Ukraine, the Group has widened the product range and finished the registration of 8 generic medicines. In Australia, the registration of the mucolytic over-the-counter drug developed by “Grindeks” was successfully finished.

Juris Bundulis, the Chairman of the Board of JSC “Grindeks”: "After looking back at the progress made in the first half of the year, I want to highlight our achievements in the Baltic States and other European Countries, where permanent increase in sales have been reached. This comes as a result from determined and continuous work, as well as demonstrates the effectiveness of our sales and marketing activities. The focus on stable, as well as new markets and widening of the product range is helping to strengthen our market position and competitiveness.”    

About “Grindeks” 

“Grindeks” is an international, vertically integrated pharmaceutical company. The main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of five subsidiary companies in Latvia, Estonia, Russia and Slovakia as well as representative offices in 13 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur®. Currently “Grindeks” produces 24 active pharmaceutical ingredients.

In 2015, products of the company were exported to 70 countries, comprising 90% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam.

To increase a production capacity and develop infrastructure, since 2002 “Grindeks” has accomplished many significant investment projects, investing more than 70 million euro over the years.

         Further information:          Laila Klavina          Head of the Communications Department, JSC “Grindeks”          Phones: (+371) 67083370, (+371) 29256012          Fax: (+371) 67083505          laila.klavina@grindeks.lv                    http://www.grindeks.lv/en

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 99

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 0

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 52

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 305

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 319

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 24

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 13

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

UP Oncolytics Boosts Funding to Propel Brain Cancer Research

Updated Category News Views 171

UP Oncolytics Secures Significant Grant for Research Advancement UP Oncolytics, a pioneering biotechnology company specializing in neuro-oncology, is making headlines with its latest achievement in funding. This innovative company, a spin-out from a prominent research institution, has secured a matching grant to further its mission in developing oncolytic virus therapy...

Continue Reading
US Dollar Weakness Fuels Gold's Safe Haven Appeal Amid Trade Tensions

Updated Category News Views 269

US Dollar Weakness Benefits Gold Amid Trade Concerns The US dollar has been retreating against several major currencies, largely influenced by recent dovish comments from Fed Governor Waller. The anticipation of further developments in trade negotiations is another factor keeping investors on edge as they navigate these financial currents. Fed’s Influence on the Dollar...

Continue Reading
Tesla's Strategic Partnerships with Local Suppliers in China

Updated Category News Views 468

Tesla's Strategic Partnerships with Local Suppliers in China Tesla, Inc. (NASDAQ: TSLA) is taking significant steps to enhance its operational efficiency and local presence in the world's largest automotive market, China. Recently reported developments indicate that the iconic electric vehicle manufacturer has successfully established partnerships with over 400 local...

Continue Reading
Collect a Unique Piece of History: Trump Bobblehead Release

Updated Category News Views 324

Royal Bobbles Launches Limited Edition Bobblehead of President-Elect Trump Add an Iconic Piece of Presidential Inauguration History with a One-of-a-Kind President-Elect Donald J. Trump Bobblehead A Historic Collectible Honoring Strength and Patriotism Royal Bobbles, recognized as the original bobblehead maker, has made an exciting announcement. They are launching the 2025...

Continue Reading
Extant Capital's New $200 Million Investment Marks Growth Path

Updated Category News Views 219

Extant Capital Receives Significant Investment Boost Extant Capital, an alternative asset management firm, has made an exciting announcement regarding a substantial new investment. The firm has successfully secured a $200 million cornerstone investment from New Holland Capital, marking a pivotal moment in its growth journey. This strategic partnership is set to enhance...

Continue Reading